marketcap
Facebook
X
TelegramGW Pharmaceuticals plc Revenue 2011-2025 | GWPH
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:
Revenue = Price * Quantity of products
Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue GW Pharmaceuticals plc
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 527 M | 311 M | 12.7 M | 11 M | 13.4 M | 43.2 M | 48.8 M | 44.1 M | 53.5 M | 46.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 527 M | 11 M | 111 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Drug manufacturers industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Evolus
EOLS
|
266 M | $ 6.49 | 1.49 % | $ 402 M |  USA |
 |
Amryt Pharma plc
AMYT
|
223 M | $ 14.7 | - | $ 621 M |  Britain |
 |
Aerie Pharmaceuticals
AERI
|
194 M | $ 15.25 | - | $ 754 M | USA |
 |
PetIQ
PETQ
|
1.1 B | $ 13.6 | 1.64 % | $ 400 M | USA |
 |
Agile Therapeutics
AGRX
|
19.6 M | $ 0.6 | 10.11 % | $ 58.2 M | USA |
 |
Teligent, Inc.
TLGT
|
45.3 M | $ 0.173 | -13.85 % | $ 16.1 M | USA |
 |
Recro Pharma
REPH
|
94.6 M | $ 1.4 | -4.76 % | $ 65.3 M | USA |
 |
Athenex
ATNX
|
103 M | $ 0.2 | -23.39 % | $ 1.76 M | USA |
 |
PLx Pharma
PLXP
|
8.21 M | $ 0.09 | -27.8 % | $ 2.56 M | USA |
 |
Shineco, Inc.
TYHT
|
23.7 M | $ 11.09 | -3.90 % | $ 97.2 M |  China |
 |
Lannett Company
LCI
|
341 M | $ 0.66 | 1.15 % | $ 7.11 M | USA |
 |
Organogenesis Holdings
ORGO
|
482 M | $ 3.87 | -3.25 % | $ 510 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
874 K | $ 40.0 | -0.1 % | $ 2.03 B |  Schweden |
 |
Adamas Pharmaceuticals, Inc.
ADMS
|
74.5 M | $ 8.22 | - | $ 376 M | USA |
 |
Perrigo Company plc
PRGO
|
4.37 B | $ 20.31 | -1.12 % | $ 2.79 B | USA |
 |
ProPhase Labs
PRPH
|
123 M | $ 0.29 | -9.29 % | $ 4.6 M | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
190 B | $ 13.49 | 0.6 % | $ 2.24 B |  India |
 |
Flexion Therapeutics, Inc.
FLXN
|
85.6 M | $ 9.12 | - | $ 459 M | USA |
 |
Happiness Biotech Group Limited
HAPP
|
89.5 M | $ 4.5 | 1.35 % | $ 17.8 M | China |
 |
Kindred Biosciences, Inc.
KIN
|
42.2 M | $ 9.25 | 0.11 % | $ 419 M | USA |
 |
Sanofi
SNY
|
37.4 B | $ 49.28 | -1.54 % | $ 66.8 B |  France |
 |
Neos Therapeutics, Inc.
NEOS
|
64.6 M | $ 1.15 | -2.54 % | $ 57.2 M | USA |
 |
Endo International plc
ENDP
|
2.01 B | $ 0.29 | - | $ 28.9 M |  Irlanda |
 |
Supernus Pharmaceuticals
SUPN
|
662 M | $ 56.69 | 1.77 % | $ 3.12 B | USA |
 |
China SXT Pharmaceuticals
SXTC
|
4.78 M | $ 1.41 | 0.01 % | $ 2.01 M | China |
 |
PPD, Inc.
PPD
|
4.68 B | $ 47.25 | 0.13 % | $ 16.6 B | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
16.5 B | $ 20.41 | -0.54 % | $ 23.1 B |  Israel |
 |
Tilray
TLRY
|
627 M | $ 1.24 | -5.34 % | $ 766 M |  Canada |
 |
Bausch Health Companies
BHC
|
8.76 B | $ 6.79 | -0.44 % | $ 2.48 B | Canada |
 |
HEXO Corp.
HEXO
|
191 M | $ 0.71 | 2.45 % | $ 38.1 M | - |
 |
Veru
VERU
|
16.9 M | $ 2.56 | -1.54 % | $ 345 M | USA |
 |
Neptune Wellness Solutions
NEPT
|
46.8 M | $ 0.2 | -45.3 % | $ 917 K | Canada |
 |
Taro Pharmaceutical Industries Ltd.
TARO
|
561 M | $ 42.97 | - | $ 1.62 B | Israel |
 |
Horizon Therapeutics Public Limited Company
HZNP
|
3.63 B | $ 116.3 | - | $ 26.6 B | Irlanda |
 |
Viatris
VTRS
|
16.3 B | $ 10.54 | 0.05 % | $ 12.8 B | USA |
 |
FSD Pharma
HUGE
|
257 K | $ 5.84 | 5743.5 % | $ 69.7 M | Canada |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.76 M | $ 0.78 | 0.86 % | $ 117 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
86 K | $ 1.3 | - | $ 55.5 M | USA |
 |
Guardion Health Sciences
GHSI
|
11 M | $ 3.25 | -0.31 % | $ 3.64 M | USA |
 |
Aurora Cannabis
ACB
|
175 M | $ 4.57 | -6.35 % | $ 86.3 M | - |
 |
Alimera Sciences
ALIM
|
80.8 M | $ 5.54 | - | $ 142 M | USA |
 |
Biogen
BIIB
|
9.68 B | $ 150.51 | -0.61 % | $ 21.9 B | USA |
|
Qilian International Holding Group Limited
QLI
|
57.1 M | $ 5.41 | -6.08 % | $ 184 M | China |
 |
Amneal Pharmaceuticals
AMRX
|
2.79 B | $ 5.91 | 2.6 % | $ 892 M | - |
 |
Ironwood Pharmaceuticals
IRWD
|
90.5 M | $ 1.87 | 0.55 % | $ 297 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
169 M | $ 18.93 | 0.08 % | $ 1.8 B | France |
 |
Cumberland Pharmaceuticals
CPIX
|
10.4 M | $ 2.7 | -2.17 % | $ 38 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
317 M | $ 2.14 | -39.89 % | $ 27.7 M | USA |